ETM
VIVO

Euclidean Technologies Management’s Meridian Bioscience Inc VIVO Stock Holding History

Euclidean Technologies Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-62,995
Closed -$2.09M – 98
2022
Q4 		$2.09M Hold
62,995
– – 1.99% 22
2022
Q3 		$1.99M Sell
62,995
-10,000
-14% -$324K 2.23% 9
2022
Q2 		$2.22M Sell
72,995
-8,000
-10% -$216K 2.29% 8
2022
Q1 		$2.1M Sell
80,995
-44,559
-35% -$1.06M 1.94% 22
2021
Q4 		$2.56M Sell
125,554
-2,534
-2% -$48.6K 2.14% 6
2021
Q3 		$2.46M Hold
128,088
– – 2.14% 10
2021
Q2 		$2.84M Buy
128,088
+12,517
+11% +$265K 2.26% 3
2021
Q1 		$3.03M Hold
115,571
– – 2.64% 4
2020
Q4 		$2.16M Buy
115,571
+40,000
+53% +$747K 2.27% 8
2020
Q3 		$1.28M Buy
+75,571
New +$1.47M 1.61% 39

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Euclidean Technologies Management's VIVO Position: Q1 2023 in Review

Euclidean Technologies Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 62,995 shares — an estimated $2.09M sold.

Euclidean Technologies Management first reported a position in VIVO in Q3 2020 and held it in 10 quarters. The position peaked at $3.03M in Q1 2021. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Euclidean Technologies Management reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Euclidean Technologies Management sold 62,995 Meridian Bioscience Inc shares in Q1 2023, an estimated $2.09M.
  • Euclidean Technologies Management first reported a position in Meridian Bioscience Inc in Q3 2020 and held it in 10 quarters.
  • Euclidean Technologies Management's Meridian Bioscience Inc position peaked at $3.03M in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Euclidean Technologies Management's 13F filing for Q1 2023, filed 26 Apr 2023.